Decreased serologic response in vaccinated military recruits during 2011 correspond to genetic drift in concurrent circulating pandemic a/H1N1 viruses

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Faix, Dennis J ^a   Hawksworth, Anthony W ^a   Myers, Christopher A ^a   Hansen, Christian J ^a   Ortiguerra, Ryan G ^a   Halpin, Rebecca ^b   Wentworth, David ^b   Pacha, Laura A ^c   Schwartz, Erica G ^d   Garcia, Shawn M S ^e   Eick Cost, Angelia A ^f   Clagett, Christopher D ^g   Khurana, Surender ^h   Golding, Hana ^h   Blair, Patrick J ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b J CRAIG VENTER INSTITUTE   (United States)

^c Army Public Health Command   (United States)

^d U S COAST GUARD   (United States)

^e Naval Hospital Beaufort   (United States)

^f Armed Forces Health Surveillance Center   (United States)

^g Navy and Marine Corps Public Health Center   (United States)

^h CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HEMAGGLUTININ ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; FATALITY; FEMALE; GENETIC DRIFT; GENETIC VARIABILITY; HA1 GENE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MALE; NONHUMAN; PROTECTION; SEQUENCE ANALYSIS; SEROCONVERSION; SOLDIER; SURFACE PLASMON RESONANCE; UNITED STATES; VIRUS GENE; VIRUS ISOLATION; VIRUS MICRONEUTRALIZATION TEST; VIRUS NEUTRALIZATION; VIRUS STRAIN; ADULT; ANTIBODY PRODUCTION; CLASSIFICATION; GENETICS; IMMUNOLOGY; INFLUENZA; PANDEMIC; PATHOGENICITY; PHYLOGENY;

TIPULA IRIDESCENT VIRUS;

ADULT; ANTIBODY FORMATION; FEMALE; GENETIC DRIFT; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MILITARY PERSONNEL; PANDEMICS; PHYLOGENY; YOUNG ADULT;

EID: 84859701266     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034581     Document Type: Article

References (60)

1. Gray GC, Callahan JD, Hawksworth AW, Fisher CA, Gaydos JC, (1999) Respiratory diseases among U.S. military personnel: countering emerging threats. Emerg Infect Dis 5: 379-385.
2. McNeill KM, Vaughn BL, Brundage MB, Li Y, Poropatich RK, et al. (2005) Clinical presentations for influenza and influenza-like illness in young, immunized soldiers. Mil Med 170: 94-97.
3. Earhart KC, Beadle C, Miller LK, Pruss MW, Gray GC, et al. (2001) Outbreak of influenza in highly vaccinated crew of U.S. Navy ship. Emerg Infect Dis 7: 463-465.
4. Ksiazek TG, Olson JG, Irving GS, Settle CS, White R, et al. (1980) An influenza outbreak due to A/USSR/77-like (H1N1) virus aboard a US Navy ship. Am J Epidemiol 112: 487-494.
5. Byerly CR, (2010) The U.S. military and the influenza pandemic of 1918-1919. Public health reports 125 (Suppl 3): 82-91.
6. Gaydos JC, Top FH Jr, Hodder RA, Russell PK, (2006) Swine influenza a outbreak, Fort Dix, New Jersey, 1976. Emerg Infect Dis 12: 23-28.
7. Sencer DJ, Millar JD, (2006) Reflections on the 1976 swine flu vaccination program. Emerg Infect Dis 12: 29-33.
8. (2009) Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR 58: 400-402.
9. Metzgar D, Baynes D, Myers CA, Kammerer P, Unabia M, et al. (2010) Initial identification and characterization of an emerging zoonotic influenza virus prior to pandemic spread. J Clin Micro 48: 4228-4234.
10. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
11. Gray GC, Goswami PR, Malasig MD, Hawksworth AW, Trump DH, et al. (2000) Adult adenovirus infections: loss of orphaned vaccines precipitates military respiratory disease epidemics. For the Adenovirus Surveillance Group. Clin Infect Dis 31: 663-670.
12. Russell KL, Hawksworth AW, Ryan MA, Strickler J, Irvine M, et al. (2006) Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004. Vaccine 24: 2835-2842.
13. Rimmelzwaan GF, McElhaney JE, (2008) Correlates of protection: novel generations of influenza vaccines. Vaccine 26 (Suppl 4): D41-44.
14. Grabenstein JD, Pittman PR, Greenwood JT, Engler RJ, (2006) Immunization to protect the US Armed Forces: heritage, current practice, and prospects. Epidemiologic reviews 28: 3-26.
15. Wang Z, Tobler S, Roayaei J, Eick A, (2009) Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 301: 945-953.
16. Myers CA, Faix DJ, Blair PJ, (2011) Possible reduced effectiveness of the 2009 H1N1 component of live, attenuated influenza vaccine. Clin Infect Dis 53: 207-208.
17. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, et al. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361: 1945-1952.
18. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, et al. (2010) Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Science Translational Medicine 2: 15ra5.
19. Burke RL, Vest KG, Eick AA, Sanchez JL, Johns MC, et al. (2011) Department of Defense influenza and other respiratory disease surveillance during the 2009 pandemic. BMC Public Health 11 (Suppl 2): S6.
20. Grotto I, Mandel Y, Green MS, Varsano N, Gdalevich M, et al. (1998) Influenza vaccine efficacy in young, healthy adults. Clin Infect Dis 26: 913-917.
21. Russell KL, Ryan MA, Hawksworth A, Freed NE, Irvine M, et al. (2005) Effectiveness of the 2003-2004 influenza vaccine among U.S. military basic trainees: a year of suboptimal match between vaccine and circulating strain. Vaccine 23: 1981-1985.
22. Eick AA, Wang Z, Hughes H, Ford SM, Tobler SK, (2009) Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members. Vaccine 27: 3568-3575.
23. Strickler JK, Hawksworth AW, Myers C, Irvine M, Ryan MA, et al. (2007) Influenza vaccine effectiveness among US military basic trainees, 2005-06 season. Emerg Infect Dis 13: 617-619.
24. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, et al. (2009) Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 361: 1260-1267.
25. Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith DD, et al. (2006) Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 25: 870-879.
26. Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, et al. (2006) Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 25: 860-869.
27. Belshe RB, Toback SL, Yi T, Ambrose CS, (2010) Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza and other respiratory viruses 4: 141-145.
28. Tasker SA, Treanor JJ, Paxton WB, Wallace MR, (1999) Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 131: 430-433.
29. Crum-Cianflone NF, Eberly LE, Duplessis C, Maguire J, Ganesan A, et al. (2011) Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 52: 138-146.
30. Boehmer LM, Waqar SN, Govindan R, (2010) Influenza vaccination in patients with cancer: an overview. Oncology 24: 1167-1170.
31. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X, (2010) Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 28: 2149-2156.
32. Ambrose CS, Levin MJ, Belshe RB, (2011) The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza and Other Respiratory Viruses 5: 67-75.
33. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, et al. (2006) Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 355: 2513-2522.
34. Miller LF, (1963) Prophylactic procedures in Navy recruits. Mil Med 128: 858-866.
35. Griffin MR, Monto AS, Belongia EA, Treanor JJ, Chen Q, et al. (2011) Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS ONE 6: e23085.
36. Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, et al. (2011) Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Inf Dis 204: 845-853.
37. He XS, Holmes TH, Mahmood K, Kemble GW, Dekker CL, et al. (2008) Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J Inf Dis 197: 803-811.
38. Forrest BD, Steele AD, Hiemstra L, Rappaport R, Ambrose CS, et al. (2011) A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Vaccine 29: 3633-3639.
39. Mallory RM, Malkin E, Ambrose CS, Bellamy T, Shi L, et al. (2010) Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS ONE 5: e13755.
40. Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, et al. (2010) Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS ONE 5: e11548.
41. Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, et al. (2011) Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J Virol 85: 1246-1256.
42. Khurana S, Wu J, Verma N, Verma S, Raghunandan R, et al. (2011) H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 85: 10945-10954.
43. Nelson M, Spiro D, Wentworth D, Beck E, Fan J, et al. (2009) The early diversification of influenza A/H1N1pdm. PLoS Currents 1: RRN1126.
44. Nelson MI, Tan Y, Ghedin E, Wentworth DE, St George K, et al. (2011) Phylogeography of the spring and fall waves of the H1N1/09 pandemic influenza virus in the United States. J Virol 85: 828-834.
45. Sharma S, Parida M, Shukla J, Rao PV, (2011) Molecular epidemiology of novel swine origin influenza virus (S-OIV) from Gwalior, India, 2009. Virology 8: 280.
46. Ilyushina NA, Khalenkov AM, Seiler JP, Forrest HL, Bovin NV, et al. (2010) Adaptation of pandemic H1N1 influenza viruses in mice. J Virol 84: 8607-8616.
47. Ye J, Sorrell EM, Cai Y, Shao H, Xu K, et al. (2010) Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype? PLoS Pathogens 6: e1001145.
48. Galiano M, Agapow PM, Thompson C, Platt S, Underwood A, et al. (2011) Evolutionary Pathways of the Pandemic Influenza A (H1N1) 2009 in the UK. PLoS ONE 6: e23779.
49. Carrat F, Flahault A, (2007) Influenza vaccine: the challenge of antigenic drift. Vaccine 25: 6852-6862.
50. Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, et al. (2010) Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE 5: e9332.
51. Rubertone MV, Brundage JF, (2002) The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Amer J Pub Health 92: 1900-1904.
52. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, et al. (1999) Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Micro 37: 937-943.
53. (2009) Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR 58: 521-524.
54. Veguilla V, Hancock K, Schiffer J, Gargiullo P, Lu X, et al. (2011) Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Micro 49: 2210-2215.
55. Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, et al. (2011) MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines. Sci Transl Med 3: 85ra48.
56. Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, et al. (2011) MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 3: 85ra48.
57. Myers CA, Kasper MR, Yasuda CY, Savuth C, Spiro DJ, et al. (2011) Dual Infection of Novel Influenza Viruses A/H1N1 and A/H3N2 in a Cluster of Cambodian Patients. Amer J Trop Med Hyg 85: 961-963.
58. Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T, et al. (2005) Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 437: 1162-1166.
59. Djikeng A, Halpin R, Kuzmickas R, Depasse J, Feldblyum J, et al. (2008) Viral genome sequencing by random priming methods. BMC Genomics 9: 5.
60. Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, et al. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS ONE 5: e11548.